[1]

Ng M, Gakidou E, Lo J, Abate YH, Abbafati C, et al. 2025. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. The Lancet 405:813−838

doi: 10.1016/S0140-6736(25)00355-1
[2]

Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, et al. 2019. Projected U.S. state-level prevalence of adult obesity and severe obesity. New England Journal of Medicine 381:2440−2450

doi: 10.1056/NEJMsa1909301
[3]

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians 75:10−45

doi: 10.3322/caac.21871
[4]

Siegel RL, Giaquinto AN, Jemal A. 2024. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians 74:12−49

doi: 10.3322/caac.21820
[5]

Gu B, Shang X, Yan M, Li X, Wang W, et al. 2021. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990−2019. Gynecologic Oncology 161:573−580

doi: 10.1016/j.ygyno.2021.01.036
[6]

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. 2008. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet 371:569−578

doi: 10.1016/S0140-6736(08)60269-X
[7]

Onstad MA, Schmandt RE, Lu KH. 2016. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. Journal of Clinical Oncology 34:4225−4230

doi: 10.1200/JCO.2016.69.4638
[8]

Nagle CM, Marquart L, Bain CJ, O’Brien S, Lahmann PH, et al. 2013. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. European Journal of Cancer 49:2717−2726

doi: 10.1016/j.ejca.2013.03.015
[9]

Tumminia A, Vinciguerra F, Parisi M, Graziano M, Sciacca L, et al. 2019. Adipose tissue, obesity and adiponectin: role in endocrine cancer risk. International Journal of Molecular Sciences 20:2863

doi: 10.3390/ijms20122863
[10]

Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. 2023. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers 15:485

doi: 10.3390/cancers15020485
[11]

Kokts-Porietis RL, Elmrayed S, Brenner DR, Friedenreich CM. 2021. Obesity and mortality among endometrial cancer survivors: a systematic review and meta-analysis. Obesity Reviews 22:e13337

doi: 10.1111/obr.13337
[12]

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine 348:1625−1638

doi: 10.1056/NEJMoa021423
[13]

Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, et al. 2021. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Network Open 4:e213520

doi: 10.1001/jamanetworkopen.2021.3520
[14]

Ross KH, Gogineni K, Subhedar PD, Lin JY, McCullough LE. 2019. Obesity and cancer treatment efficacy: existing challenges and opportunities. Cancer 125:1588−1592

doi: 10.1002/cncr.31976
[15]

Helyer LK, Varnic M, Le LW, Leong W, McCready D. 2010. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. The Breast Journal 16:48−54

doi: 10.1111/j.1524-4741.2009.00855.x
[16]

Gunderson CC, Java J, Moore KN, Walker JL. 2014. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecologic Oncology 133:23−27

doi: 10.1016/j.ygyno.2014.01.041
[17]

Wahl S, Drong A, Lehne B, Loh M, Scott WR, et al. 2017. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature 541:81−86

doi: 10.1038/nature20784
[18]

Keleher MR, Zaidi R, Hicks L, Shah S, Xing X, et al. 2018. A high-fat diet alters genome-wide DNA methylation and gene expression in SM/J mice. BMC Genomics 19:888

doi: 10.1186/s12864-018-5327-0
[19]

Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, et al. 1999. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. The American Journal of Pathology 155:1767−1772

doi: 10.1016/S0002-9440(10)65492-2
[20]

Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, et al. 2001. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. International Journal of Cancer 91:22−26

doi: 10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s
[21]

Yang HJ, Liu VWS, Wang Y, Tsang PCK, Ngan HYS. 2006. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6:212

doi: 10.1186/1471-2407-6-212
[22]

Nosho K, Shima K, Irahara N, Kure S, Baba Y, et al. 2009. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clinical Cancer Research 15:3663−3671

doi: 10.1158/1078-0432.CCR-08-2383
[23]

Sheaffer KL, Elliott EN, Kaestner KH. 2016. DNA hypomethylation contributes to genomic instability and intestinal cancer initiation. Cancer Prevention Research 9:534−546

doi: 10.1158/1940-6207.CAPR-15-0349
[24]

Inoue F, Sone K, Toyohara Y, Takahashi Y, Kukita A, et al. 2021. Targeting epigenetic regulators for endometrial cancer therapy: its molecular biology and potential clinical applications. International Journal of Molecular Sciences 22:2305

doi: 10.3390/ijms22052305
[25]

Xiong Y, Dowdy SC, Xue A, Jiang S, Eberhardt NL, et al. 2005. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecologic Oncology 96:601−609

doi: 10.1016/j.ygyno.2004.11.047
[26]

Levine DA. 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497:67−73

doi: 10.1038/nature12113
[27]

Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, et al. 2016. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Research 44:e71

doi: 10.1093/nar/gkv1507
[28]

Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, et al. 2013. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8:203−209

doi: 10.4161/epi.23470
[29]

Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, et al. 2010. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11:587

doi: 10.1186/1471-2105-11-587
[30]

Law CW, Alhamdoosh M, Su S, Dong X, Tian L, et al. 2016. RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. F1000Research 5:1408

doi: 10.12688/f1000research.9005.3
[31]

Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, et al. 2016. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research 44:W90−W97

doi: 10.1093/nar/gkw377
[32]

Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, et al. 2018. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nature Communications 9:5416

doi: 10.1038/s41467-018-07901-8
[33]

Győrffy B. 2024. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. The Innovation 5:100625

doi: 10.1016/j.xinn.2024.100625
[34]

Minagawa T, Ijuin T, Mochizuki Y, Takenawa T. 2001. Identification and characterization of a sac domain-containing phosphoinositide 5-phosphatase. Journal of Biological Chemistry 276:22011−22015

doi: 10.1074/jbc.M101579200
[35]

Bai D, Zhang Y, Shen M, Sun Y, Xia Q, et al. 2016. Hyperglycemia and hyperlipidemia blunts the Insulin-Inpp5f negative feedback loop in the diabetic heart. Scientific Reports 6:22068

doi: 10.1038/srep22068
[36]

Kim HS, Li A, Ahn S, Song H, Zhang W. 2014. Inositol Polyphosphate-5-Phosphatase F (INPP5F) inhibits STAT3 activity and suppresses gliomas tumorigenicity. Scientific Reports 4:7330

doi: 10.1038/srep07330
[37]

Winder A, Unno K, Yu Y, Lurain J, Kim JJ. 2017. The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer. Cancer Biology & Therapy 18:958−964

doi: 10.1080/15384047.2017.1281496
[38]

Lee, II, Maniar K, Lydon JP, Kim JJ. 2016. Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells. Oncogene 35:5191−5201

doi: 10.1038/onc.2016.56
[39]

Pant A, Lee, II, Lu Z, Rueda BR, Schink J, et al. 2012. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One 7:e41593

doi: 10.1371/journal.pone.0041593
[40]

Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, et al. 2008. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecologic Oncology 108:609−618

doi: 10.1016/j.ygyno.2007.11.007
[41]

Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, et al. 2008. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149:1942−1950

doi: 10.1210/en.2007-0756
[42]

Hopkins BD, Goncalves MD, Cantley LC. 2020. Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nature Reviews Endocrinology 16:276−283

doi: 10.1038/s41574-020-0329-9
[43]

Asif H, Foley G, Simon M, Roque D, Kim JJ. 2023. Analysis of endometrial carcinoma TCGA reveals differences in DNA methylation in tumors from Black and White women. Gynecologic Oncology 170:1−10

doi: 10.1016/j.ygyno.2022.12.011
[44]

Porta C, Paglino C, Mosca A. 2014. Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology 4:64

doi: 10.3389/fonc.2014.00064
[45]

Milner JJ, Chen ZF, Grayson J, Shiao SPK. 2022. Obesity-associated differentially methylated regions in colon cancer. Journal of Personalized Medicine 12:660

doi: 10.3390/jpm12050660
[46]

Hair BY, Troester MA, Edmiston SN, Parrish EA, Robinson WR, et al. 2015. Body mass index is associated with gene methylation in estrogen receptor–positive breast tumors. Cancer Epidemiology, Biomarkers & Prevention 24:580−586

doi: 10.1158/1055-9965.EPI-14-1017
[47]

Yamagata Y, Asada H, Tamura I, Lee L, Maekawa R, et al. 2009. DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen. Human Reproduction 24:1126−1132

doi: 10.1093/humrep/dep015
[48]

Nagashima M, Miwa N, Hirasawa H, Katagiri Y, Takamatsu K, et al. 2019. Genome-wide DNA methylation analysis in obese women predicts an epigenetic signature for future endometrial cancer. Scientific Reports 9:6469

doi: 10.1038/s41598-019-42840-4
[49]

Asif H, Kim JJ. 2025. Comparing self-reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models. Molecular Oncology 19:3596−3612

doi: 10.1002/1878-0261.70013
[50]

Simancas-Racines D, Campuzano-Donoso M, Román-Galeano NM, Zambrano-Villacres R, Memoli P, et al. 2025. Obesity and endometrial cancer: biological mechanisms, nutritional strategies, and clinical perspectives. Food and Agricultural Immunology 36:2510961

doi: 10.1080/09540105.2025.2510961
[51]

He L, Jiang Z, Wang J, Han Z. 2025. Mechanism of miR-200b-3p-induced FOSL2 inhibition of endometrial cancer cell proliferation and metastasis. Scientific Reports 15:15742

doi: 10.1038/s41598-025-00224-x
[52]

Wang C, Su K, Zhang Y, Zhang W, Zhao Q, et al. 2019. IR-A/IGF-1R-mediated signals promote epithelial-mesenchymal transition of endometrial carcinoma cells by activating PI3K/AKT and ERK pathways. Cancer Biology & Therapy 20:295−306

doi: 10.1080/15384047.2018.1529096
[53]

Wen Y, Chen Y, Ma Y, Lu C, Liu Y, et al. 2025. Long-term BMI trajectories and epigenetic age acceleration: the role of genetic risk for obesity. BMC Medicine 23:589

doi: 10.1186/s12916-025-04410-6